DF1001

DRUG2 trials

Sponsors

Dragonfly Therapeutics Inc., Dragonfly Therapeutics

Conditions

Locally Advanced or Metastatic Solid TumorsSolid Tumor, Adultand Expansion in Selected Indications

Phase 1

Study of DF1001 in Patients With Advanced Solid Tumors

CompletedNCT04143711

Dragonfly TherapeuticsSolid Tumor, Adult

Start: 2019-11-11End: 2025-12-05Updated: 2026-03-18

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

CompletedCTIS2023-503291-24-00

Dragonfly Therapeutics Inc.and Expansion in Selected Indications, Locally Advanced or Metastatic Solid Tumors

Start: 2021-03-17End: 2025-12-03Target: 174Updated: 2025-08-25

Related Papers

Abstract P4-08-23: Preclinical characterization of DF1001, a first-in-class dual NK and T cell engager targeting HER2-high or HER2-low tumors

Clinical Cancer Research2025-06-13

Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.

Journal of Clinical Oncology2023-06-0123 citations